AKT plays a crucial role in gastric cancer (Review)

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 607-611

  Sasaki, Takamitsu ^a   Yamashita, Yuichi ^a   Kuniyasu, Hiroki ^b  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic gastritis; Helicobacter pylori; hTERT; Telomerase

Indexed keywords

PROTEIN KINASE B; TELOMERASE;

CANCER GROWTH; CELL PROLIFERATION; CHRONIC GASTRITIS; GENE MUTATION; GENE OVEREXPRESSION; HELICOBACTER INFECTION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TELOMERE SHORTENING; UBIQUITINATION;

EID: 84931373699     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3260     Document Type: Review

References (49)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Yokozaki H, Kuniyasu H, Semba S, Yasui W and Tahara E: Molecular bases of human stomach carcinogenesis. Mol Pathol Gastroenterol Cancer. Tahara E (ed.) Springer-Verlag, Tokyo, pp 55-70, 1997.
3. Kuniyasu H, Yasui W, Yokozaki H and Tahara E: Helicobacter pylori infection and carcinogenesis of the stomach. Langenbecks Arch Surg 385: 69-74, 2000.
4. IARC: Schistosomes, Liver Flukes and Hericobactor pylori. IARC Sci, 1994.
5. Tsukamoto T and Tatematsu M: Role of Helicobacter pylori in gastric neoplasia. Curr Infect Dis Rep 16: 402, 2014.
6. Sukawa Y, Yamamoto H, Nosho K, et al: Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 18: 6577-6586, 2012.
7. Berg M and Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 14: 207-214, 2012.
8. Ng L, Poon RT and Pang R: Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 70: 3631-3656, 2013.
9. Cheung M and Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets, 2013.
10. Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15: 177-182, 2004.
11. Radisavljevic Z: AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol 228: 21-24, 2013.
12. Xu M and Mo YY: The Akt-associated microRNAs. Cell Mol Life Sci 69: 3601-3612, 2012.
13. Sasaki T, Kuniyasu H, Luo Y, et al: Increased phosphorylation of AKT in high-risk gastric mucosa. Anticancer Res 33: 3295-3300, 2013.
14. Ho SB: Premalignant lesions of the stomach. Semin Gastrointest Dis 7: 61-73, 1996.
15. Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4: 688-694, 2004.
16. Higashi H, Tsutsumi R, Muto S, et al: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295: 683-686, 2002.
17. You M, Yu DH and Feng GS: Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19: 2416-2424, 1999.
18. Tosh D and Slack JM: How cells change their phenotype. Nat Rev Mol Cell Biol 3: 187-194, 2002.
19. Ochiai A and Hirohashi S: Genetic alteration in the precursors of gastric cancer. Mol Pathol Gastroenterol Cancer. Tahara E (ed.) Springer-Verlag, Tokyo pp 43-53, 1997.
20. Sugano K: Premalignant conditions of gastric cancer. J Gastroenterol Hepatol 28: 906-911, 2013.
21. Testino G: Helicobacter pylori, cell proliferation and carcinogenesis. Am J Gastroenterol 96: 2514, 2001.
22. Guerci A, Chambre JF, Franck P, Floquet J, Gaucher P and Guerci O: Flow cytometric analysis of the cell cycle in chronic gastritis. Anal Cell Pathol 4: 381-388, 1992.
23. Tahara E, Kuniyasu H, Yasui W and Yokozaki H: Gene alterations in intestinal metaplasia and gastric cancer. Eur J Gastroenterol Hepatol (6 Suppl 1): 102, 1994.
24. Ochiai A, Yamauchi Y and Hirohashi S: p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 69: 28-33, 1996.
25. Semba S, Yokozaki H, Yamamoto S, Yasui W and Tahara E: Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 77: 1620-1627, 1996.
26. Blackburn EH: Switching and signaling at the telomere. Cell 106: 661-673, 2001.
27. Lingner J, Cooper JP and Cech TR: Telomerase and DNA end replication: no longer a lagging strand problem? Science 269: 1533-1534, 1995.
28. Stewart SA and Weinberg RA: Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 22: 531-557, 2006.
29. Tahara H, Kuniyasu H, Yokozaki H, et al: Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1: 1245-1251, 1995.
30. Feng J, Funk WD, Wang SS, et al: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
31. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650, 1996.
32. Blasco MA, Rizen M, Greider CW and Hanahan D: Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 12: 200-204, 1996.
33. Kuniyasu H, Domen T, Hamamoto T, et al: Expression of human telomerase RNA is an early event of stomach carcinogenesis. Jpn J Cancer Res 88: 103-107, 1997.
34. Weiss H, Gutz HJ, Schroter J and Wildner GP: DNA distribution pattern in chronic gastritis. I. DNA ploidy and cell cycle distribution. Scand J Gastroenterol 24: 643-648, 1989.
35. Kuniyasu H, Kitadai Y, Mieno H and Yasui W: Helicobactor pylori infection is closely associated with telomere reduction in gastric mucosa. Oncology 65: 275-282, 2003.
36. Autexier C and Lue NF: The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 75: 493-517, 2006.
37. Angrisano T, Lembo F, Peluso S, Keller S, Chiariotti L and Pero R: Helicobacter pylori regulates iNOS promoter by histone modifications in human gastric epithelial cells. Med Microbiol Immunol 201: 249-257, 2012.
38. Murata M, Thanan R, Ma N and Kawanishi S: Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012: 623019, 2012.
39. Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G and Wilkinson M: Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer 7: 97, 2007.
40. Li H, Zhao L, Yang Z, Funder JW and Liu JP: Telomerase is controlled by protein kinase C alpha in human breast cancer cells. J Biol Chem 273: 33436-33442, 1998.
41. Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274: 13085-13090, 1999.
42. Kim JH, Park SM, Kang MR, et al: Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 19: 776-781, 2005.
43. Sasaki T, Kuniyasu H, Luo Y, et al: AKT activation and telomerase reverse transcriptase expression are concurrently associated with prognosis of gastric cancer. Pathobiology 81: 36-41, 2014.
44. Populo H, Lopes JM and Soares P: The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 13: 1886-1918, 2012.
45. Karamitopoulou E: Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol 2: 209, 2012.
46. Liu Z, Li Q, Li K, et al: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32: 4203-4213, 2012.
47. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
48. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273: 114-127, 2013.
49. Karar J and Maity A: PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4: 51, 2011.